Omeros Total Assets 2009-2018 | OMER

Omeros total assets from 2009 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
Omeros Annual Total Assets
(Millions of US $)
2018 $96
2017 $116
2016 $67
2015 $49
2014 $11
2013 $17
2012 $27
2011 $27
2010 $46
2009 $62
2008 $22
2007 $0
Omeros Quarterly Total Assets
(Millions of US $)
Q4 2018 $96
Q3 2018 $76
Q2 2018 $106
Q1 2018 $89
Q4 2017 $116
Q3 2017 $126
Q2 2017 $60
Q1 2017 $58
Q4 2016 $67
Q3 2016 $73
Q2 2016 $46
Q1 2016 $36
Q4 2015 $49
Q3 2015 $41
Q2 2015 $59
Q1 2015 $75
Q4 2014 $11
Q3 2014 $25
Q2 2014 $41
Q1 2014 $56
Q4 2013 $17
Q3 2013 $12
Q2 2013 $23
Q1 2013 $18
Q4 2012 $27
Q3 2012 $33
Q2 2012 $10
Q1 2012 $21
Q4 2011 $27
Q3 2011 $35
Q2 2011 $41
Q1 2011 $48
Q4 2010 $46
Q3 2010 $37
Q2 2010 $45
Q1 2010 $53
Q4 2009 $62
Q3 2009 $7
Q2 2009 $0
Q1 2009 $0
Q4 2008 $0
Q3 2008 $0
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.930B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $134.809B 26.28
Medtronic (MDT) Ireland $114.856B 16.79
Stryker (SYK) United States $69.039B 24.64
Boston Scientific (BSX) United States $49.279B 23.63
Baxter (BAX) United States $38.988B 25.01
Zimmer Biomet Holdings (ZBH) United States $25.460B 16.29
Smith & Nephew SNATS (SNN) United Kingdom $16.746B 0.00
Canopy Growth (CGC) Canada $16.646B 0.00
ResMed (RMD) United States $14.578B 27.64
Aurora Cannabis (ACB) Canada $9.230B 65.07
Bio-Rad Laboratories (BIO) United States $8.754B 50.22
Perrigo (PRGO) Ireland $6.685B 10.84
Hill-Rom Holdings (HRC) United States $6.417B 19.85
Insulet (PODD) United States $4.971B 1666.40
GW Pharmaceuticals (GWPH) United Kingdom $4.857B 0.00
ICU Medical (ICUI) United States $4.694B 29.07
Haemonetics (HAE) United States $4.319B 38.31
Hutchison China MediTech (HCM) China $3.951B 0.00
Agios Pharmaceuticals (AGIO) United States $3.335B 0.00
NuVasive (NUVA) United States $3.048B 26.48
Neogen (NEOG) United States $3.014B 49.01
Quidel (QDEL) United States $2.477B 22.16
National Vision Holdings (EYE) United States $2.284B 44.94
Aphria (APHA) $1.955B 0.00
HEXO (HEXO) $1.502B 0.00
Phibro Animal Health (PAHC) United States $1.342B 19.28
VAREX IMAGING (VREX) United States $1.234B 24.16
Cardiovascular Systems (CSII) United States $1.222B 877.50
AtriCure (ATRC) United States $1.081B 0.00
Lantheus Holdings (LNTH) United States $0.962B 26.00
PetIQ (PETQ) United States $0.874B 25.02
Cerus (CERS) United States $0.826B 0.00
MacroGenics (MGNX) United States $0.805B 0.00
NanoString Technologies (NSTG) United States $0.759B 0.00
Evolus (EOLS) United States $0.721B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.720B 24.51
TG Therapeutics (TGTX) United States $0.706B 0.00
OraSure Technologies (OSUR) United States $0.596B 25.95
Surmodics (SRDX) United States $0.585B 85.02
LeMaitre Vascular (LMAT) United States $0.554B 26.32
Meridian Bioscience (VIVO) United States $0.551B 16.42
Quanterix (QTRX) United States $0.500B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.344B 0.00
Insys Therapeutics (INSY) United States $0.321B 0.00
Utah Medical Products (UTMD) United States $0.319B 20.75
BioLife Solutions (BLFS) United States $0.308B 127.08
Vapotherm (VAPO) United States $0.283B 0.00
Rockwell Medical (RMTI) United States $0.263B 0.00
Cytosorbents (CTSO) United States $0.223B 0.00
Owens & Minor (OMI) United States $0.214B 2.93
Zynex (ZYXI) United States $0.175B 18.69
Bovie Medical (APYX) United States $0.149B 0.00
Chimerix (CMRX) United States $0.129B 0.00
Fonar (FONR) United States $0.128B 6.85
Chembio Diagnostics (CEMI) United States $0.123B 0.00
Surface Oncology (SURF) United States $0.112B 0.00
United-Guardian (UG) United States $0.088B 20.27
Female Health (VERU) United States $0.086B 0.00
InfuSystems Holdings (INFU) United States $0.083B 0.00
Neurotrope (NTRP) United States $0.076B 0.00
Trinity Biotech (TRIB) Ireland $0.067B 19.86
Oramed Pharmaceuticals (ORMP) United States $0.066B 0.00
GUARDION HEALTH (GHSI) United States $0.049B 0.00
ImmuCell (ICCC) United States $0.044B 0.00
Senestech (SNES) United States $0.035B 0.00
Valeritas Holdings (VLRX) United States $0.030B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.025B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.014B 0.00
Cellectar Biosciences (CLRB) United States $0.013B 0.00
Akers Biosciences Inc (AKER) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.007B 12.64